Emcure Pharmaceuticals reports Q1 FY26 consolidated PAT higher at Rs. 206.95 Cr

Emcure Pharmaceuticals has reported total income of Rs. 2,104.23 crores during the period ended June 30, 2025

Lupin launches Glucagon for Injection USP, 1mg/Vial in US

Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus

Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP

Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle

Divis Laboratories posts consolidated Q1 FY26 PAT of Rs. 545 Cr

Divi's Laboratories has reported total income of Rs. 2,529 crores during the period ended June 30, 2025

Morepen Laboratories consolidated Q1 FY26 PAT lower at Rs. 11.40 Cr

Morepen Laboratories has reported total income of Rs. 429.64 crores during the period ended June 30, 2025

KIMS Q1 FY26 consolidated profit slips to Rs. 78.6 Cr

KIMS has reported total income of Rs. 878.7 crores during the period ended June 30, 2025

Wockhardt reports Q1 FY26 loss at Rs. 108 Cr

Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a

Gandhar Oil Refinery (India) reports Q1 FY26 consolidated PAT lower at Rs. 26.1 Cr YoY

Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr

Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore

Zydus receives final approval from USFDA for Prucalopride Tablets

Prucalopride is prescribed for chronic idiopathic constipation